<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0011998'>Postprandial hyperglycemia</z:hpo> characterizes early type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether ameliorating <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> with <z:chebi fb="0" ids="2376">acarbose</z:chebi> would prevent or delay progression of <z:mp ids='MP_0002055'>diabetes</z:mp>, defined as progression to frank fasting <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, in subjects with early <z:mp ids='MP_0002055'>diabetes</z:mp> (fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> [FPG] &lt;140 mg/dl and 2-h plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> &gt; or =200 mg/dl) </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Two hundred nineteen subjects with early <z:mp ids='MP_0002055'>diabetes</z:mp> were randomly assigned to 100 mg <z:chebi fb="0" ids="2376">acarbose</z:chebi> t.i.d. or identical placebo and followed for 5 years or until they reached the primary outcome (two consecutive quarterly FPG measurements of &gt; or =140 mg/dl) </plain></SENT>
<SENT sid="3" pm="."><plain>Secondary outcomes included measures of glycemia (meal tolerance tests, HbA(1c), annual oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests [OGTTs]), measures of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (homeostasis model assessment [HOMA] of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and insulin sensitivity index from hyperglycemic clamps), and secondary measures of beta-cell function (HOMA-beta, early- and late-phase insulin secretion, and proinsulin-to-insulin ratio) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="2376">Acarbose</z:chebi> significantly reduced <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>However, there was no difference in the cumulative rate of frank fasting <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (29% with <z:chebi fb="0" ids="2376">acarbose</z:chebi> and 34% with placebo; P = 0.65 for survival analysis) </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant differences between groups in OGTT values, measures of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, or secondary measures of beta-cell function </plain></SENT>
<SENT sid="7" pm="."><plain>In a post hoc analysis of subjects with initial FPG &lt;126 mg/dl, <z:chebi fb="0" ids="2376">acarbose</z:chebi> reduced the rate of development of FPG &gt; or =126 mg/dl (27 vs. 50%; P = 0.04) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Ameliorating <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> did not appear to delay progression of early type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Factors other than <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> may be greater determinants of progression of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Alternatively, once FPG exceeds 126 mg/dl, beta-cell failure may no longer be remediable </plain></SENT>
</text></document>